Basel, Switzerland
Anaveon is a Swiss-based startup that was founded in 2017. The company focuses on developing biologics to modulate the functions of cytokines, aiming to provide substantial therapeutic benefits, particularly for cancer patients. With its slogan "From Cytokines to Therapies," Anaveon is dedicated to innovative approaches in the biotech industry.
The most recent milestone for Anaveon was achieving a significant Fr.110.00M Series B investment on 16 December 2021. This investment round attracted notable participation from Novartis Venture Fund, Pontifax, Forbion, Cowen Digital, Syncona Investment Management, and Pfizer Venture Investments.
This recent investment reflects a high level of confidence from major players in the biotech and pharmaceutical sectors in the potential of Anaveon's approach and the impact it can make in the field. The strong support from such renowned investors underscores the promising nature of the company's work and its potential for future growth and success.
With the backing of key industry players and a clear focus on addressing critical medical needs, Anaveon is well-positioned to continue its trajectory of innovation and make significant contributions to the advancement of cytokine modulation therapies.
